Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

Table 2

Incidence of fractures.

Age	Hip	NHNV	Morphometric vertebral^†	Clinical vertebral^‡
75–79	0.0053	0.0076	0.2	0.0045
80–84	0.0060	0.0203	0.2	0.0045
85+	0.0150	0.0291	0.2	0.0133

Source: Melton et al. 1999 [33].
^†Source: Hasserius et al. 2003 [34]; value shown is prevalence.
^‡Source: Cooper et al. 1992 [35].